Navigation Links
Medivir Announces an Interferon-Free Phase II Combination Trial With TMC435 and daclatasvir to Commence Shortly
Date:6/28/2012

STOCKHOLM, Sweden, June 29, 2012 /PRNewswire/ --

  • The phase II interferon-free combination study with TMC435 and daclatasvir will evaluate treatment-naïve or previous null responder patients with HCV genotype 1a and 1b
  • The study will include approx. 180 patients and will evaluate a combination of TMC435 and daclatasvir, with or without Ribavirin, in four different cohorts for 12 or 24 weeks of treatment

Medivir AB (OMX:MVIR), the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that a phase II combination study with the investigational compound TMC435 and Bristol-Myers Squibb's investigational compound daclatasvir will start in July. This study is part of the clinical collaboration agreement between Janssen R&D Ireland and Bristol-Myers Squibb Company (NYSE: BMY) announced on 2 December 2011 and on 18 April 2012.

TMC435 and daclatasvir (BMS-790052)

TMC435, a once daily potent NS3/4A protease inhibitor (PI) in phase III clinical development for the treatment of chronic genotype-1 hepatitis C virus (HCV) infection, will be investigated in an interferon free  phase II trial in combination with Bristol-Myers Squibb´s investigational NS5A replication complex inhibitor, daclatasvir (BMS-790052), also in phase III development.

The purpose of this study is to assess the efficacy and safety of TMC435 and daclatasvir in combination with or without Ribavirin in chronic genotype-1 hepatitis C infected patients who are treatment-naive or null responders to previous Peginterferon alfa/Ribavirin therapy.

Study design

In this open label phase II study the potential to achieve sustained viral response (SVR), 12 (SVR12) and 24 (SVR24) weeks post treatment in treatment-naïve and
'/>"/>

SOURCE Medivir
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hanger, Inc. Announces Second Quarter 2012 Earnings Release Conference Call
2. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
3. Marshall Edwards Announces Name Change to MEI Pharma ("MEIP")
4. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
5. Practice Fusion Announces $34 Million in Financing Led by Artis Ventures
6. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
7. Detroit Metro Convention & Visitors Bureau announces launch of Medical Meetings Initiative; recruits top leaders to Advisory Council
8. DATATRAK Announces Accreditation Program
9. Golden Meditech Holdings Limited Announces 2011/ 2012 Annual Results
10. Global Information, Inc. Announces New Market Forecasts For Drug Discovery Industry as it Emerges from Recession
11. Omeros Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Deutschland, 31. Juli 2014  invendo medical ... („robotischen") Koloskopie-Systems für den Einmalgebrauch, verkündete heute, ... weltweit anerkannter Manager im Bereich Medizintechnik, als ... stößt. Logo - ... hochangesehener globaler Visionär der Medizintechnikbranche. Er war ...
(Date:7/31/2014)... July 31, 2014 Nutrastar International Inc. (OTCQB: ... supplier of premium branded consumer products, including commercially cultivated ... foods, today announced the signing of its first distributor ... expansion to Hubei Province ... Central China . The contract ...
(Date:7/31/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... $70.1 million for the second quarter ended June 30, ... revenue for the same period of 2013. ... Assist Systems were sold globally compared to 523 units ...
Breaking Medicine Technology:invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 2HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 5HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 6HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 7HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 8HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 9HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 10HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 11HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 12
... Who Take DHA Have Healthier Pregnancies, Fewer Premature Births, ... nutritional,experts from a European Union (EU) committee now recommend ... basis with a large amount,of DHA, an essential omega-3 ... growing array of health benefits, nutritional,supplementation of DHA is ...
... Agent Administered in First-In-Human Study to Cancer Patients, ... Pharmaceuticals, Inc.,today announced that its first-in-humans Phase 1 ... is designed to evaluate the safety,pharmacokinetic and pharmacodynamic ... tumors. Study sites include TGen Clinical Research at,Scottsdale ...
Cached Medicine Technology:European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day 2Prolexys Pharmaceuticals Initiates Phase 1 Study 2
(Date:7/31/2014)... Ottawa, Ontario (PRWEB) July 31, 2014 ... s deliver fitness to your home, which now includes ... certified personal trainers have been delivering fitness to clients ... Ottawa. Fitness on the Go is a Canadian owned ... to helping communities achieve a healthier and fitter lifestyle. ...
(Date:7/31/2014)... July 31, 2014 In a front-page ... pharmaceutical giant, Johnson & Johnson, is withdrawing its laparoscopic ... spread undetected cancer. This important story has also ... Today (7/31), the AP (7/30), the Pittsburgh Business Times ... is used during uterine procedures to, “slice up common ...
(Date:7/31/2014)... ARBORA new bill introduced in Congress with bipartisan support ... University of Michigan research, which could improve the health ... spend on the medicines and tests they need most. ... Diane Black and Earl Blumenauer, grew out of a ... the U-M,s Institute for Healthcare Policy and Innovation. It ...
(Date:7/31/2014)... 2014 Dr. Jeff Drake at Drake ... known chiropractors in the area and he has really made ... He is constantly working with new and return patients to ... Those who are in pain or experience daily suffering should ... those who have never visited Drake Chiropractic, Dr. Drake is ...
(Date:7/31/2014)... Long associated with enabling the proliferation of ... by Heat-Shock Factor 1 (HSF1) can also turn ... support malignant progression and metastasis. , The finding, ... the journal Cell , lends new insights ... diagnosis, prognosis, and management of cancer patients. ...
Breaking Medicine News(10 mins):Health News:Fitness on the Go Grows to Ottawa 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 3Health News:Drake Chiropractic Offers Special to New Patients in Wichita 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 3
... suffering encountered by men who underwent surgery for hernia was ... delayed surgeries and felt almost no symptoms, after a period ... were also reported to be the same. Most men who ... either minimally symptomatic or asymptomatic. They usually wait until the ...
... doctors and pharmacists in the U.S. are not aware that ... drugs of the same brand name or a similar sounding ... U.S. Food and Drug Administration (FDA) //said medication name mix-ups ... buying and using the wrong medicine. ...
... 12 babies born in New South Wales are due to ... obstetricians working at the private hospitals. ,About 25% ... drugs to initiate labour. // ,The doctors when asked ... as they want that particular doctor to handle their pregnancy. ...
... upset and has sent a letter to the acting head of ... letter he had asked the FDA to provide a full account ... reveled that the tainted tissues were used for the patients in ... into the matter about the case of the Brooklyn funeral home ...
... incidence of Polio in Bihar state has led to much ... state stands unparalled with respect to the number of polio ... for provision of polio drops to children less than 5 ... recently. ,National Cadet Corps volunteers embarked on ...
... The Royal National Institute of Deaf People with collaboration with ... aims at checking the hearing capacity of 28 million people ... is estimated that more than 4 million people in United ... to be treated which requires early diagnosis. ,The ...
Cached Medicine News:Health News:Drug Name Confusion Makes Imports Dangerous: FDA 2Health News:New trend of birth induction is on the rise 2Health News:Bihar Health Officials Worried As Polio Cases Soar 2
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
... The DRS 2000, a uniquely intelligent system, offers ... space saving, 2-level design. Up to 27 reservoirs ... give you the flexibility to tailor your staining ... Two start stations allow for continuous loading; The ...
Medicine Products: